Opzelura, Dermavant’s Vtama cream hits goal in eczema phase 3 study
March 16, 2023
Source: drugdu
244
Incyte’s Opzelura cream may be looking at a new competitive rival in the lucrative atopic dermatitis field.
Wednesday, Dermavant Sciences said its topical drug Vtama has come out successful in the first of two phase 3 studies the company is running in atopic dermatitis.
As William Blair analysts see it, Vtama’s results put it “in reach of Opzelura on efficacy,” although one important data point remains unknown.
In a phase 3 trial called ADORING 2, 46.4% of eczema patients who received the Vtama cream enjoyed clear or almost clear skin at week 8 while demonstrating at least a two-grade improvement from baseline. Vtama’s skin clearance rate was higher than the 18% observed in control patients who got a dummy therapy.
Vtama also aced other secondary endpoints. The topical AHR agonist helped 59.1% of patients experience a 75% reduction from baseline in the Eczema Area and Severity Index (EASI), versus 21.2% in the control arm. It also outperformed the control cream at reducing itching on a scorecard called PP-NRS.
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Over 5.7 billion! China’s dual antibody ADC goes global+1 November 21, 2024
- Is Jingtai Technology once again breaking through the “first AI pharmaceutical stock” halo and shedding? November 21, 2024
- Yangqi Medical Chip completes tens of millions of yuan in Pre-A round financing November 21, 2024
- Endovascular stent approved through priority green channel November 21, 2024
- Well-known products of foreign companies such as AZ, Eli Lilly, and Sanofi were disqualified November 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
